Clearside Biomedical, Inc.
US ˙ NasdaqGM ˙ US1850631045

Introduction

This page provides a comprehensive analysis of the known insider trading history of Deignan Charles A.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Deignan Charles A. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CLSD / Clearside Biomedical, Inc. Chief Financial Officer 384,662
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Deignan Charles A.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CLSD / Clearside Biomedical, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CLSD / Clearside Biomedical, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-11-12 CLSD Deignan Charles A. 7,500 1.1400 7,500 1.1400 8,550 80 3.7700 19,725 230.70
2019-03-15 CLSD Deignan Charles A. 10,000 1.3600 10,000 1.3600 13,600
2018-03-23 CLSD Deignan Charles A. 500 11.7900 500 11.7900 5,895
2017-08-14 CLSD Deignan Charles A. 1,000 7.0650 1,000 7.0650 7,065

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CLSD / Clearside Biomedical, Inc. Insider Trades
Insider Sales CLSD / Clearside Biomedical, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CLSD / Clearside Biomedical, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-01-19 CLSD Deignan Charles A. 12,900 1.2800 12,900 1.2800 16,512 336 0.8723 -5,259 -31.85
2016-06-07 CLSD Deignan Charles A. 2 7.0000 2 7.0000 14

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CLSD / Clearside Biomedical, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Deignan Charles A. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-01-19 2024-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -12,900 384,662 -3.24 1.28 -16,512 492,367
2023-09-13 2023-09-13 4 CLSD Clearside Biomedical, Inc.
Common Stock
M - Exercise 34,090 397,562 9.38 0.40 13,636 159,025
2023-01-20 2023-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale X -14,030 363,472 -3.72 1.50 -21,045 545,208
2022-12-20 2022-12-20 4 CLSD Clearside Biomedical, Inc.
Common Stock
M - Exercise 23,636 377,502 6.68 0.40 9,454 151,001
2022-01-28 2022-01-18 4/A CLSD Clearside Biomedical, Inc.
Stock Option (Right to Buy)
A - Award 138,750 138,750
2022-01-28 2022-01-18 4/A CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 46,250 362,699 14.62
2022-01-20 2022-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale X -8,833 351,366 -2.45 2.09 -18,461 734,355
2022-01-20 2022-01-18 4 CLSD Clearside Biomedical, Inc.
Stock Option (Right to Buy)
A - Award 131,250 131,250
2022-01-20 2022-01-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 43,750 360,199 13.83
2021-09-23 2021-09-21 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale X -2,800 316,449 -0.88 6.41 -17,948 2,028,438
2021-06-23 2021-06-21 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale X -2,938 319,249 -0.91 4.37 -12,839 1,395,118
2021-01-20 2021-01-18 4 CLSD Clearside Biomedical, Inc.
Stock Option (Right to Buy)
A - Award 195,640 195,640
2021-01-20 2021-01-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 96,360 322,187 42.67
2020-06-03 2020-06-01 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale X -14,992 220,827 -6.36 1.88 -28,185 415,155
2020-01-10 2020-01-08 4 CLSD Clearside Biomedical, Inc.
Stock Option (Right to Buy)
A - Award 75,000 75,000
2020-01-10 2020-01-08 4 CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 25,000 228,856 12.26
2019-11-13 2019-11-12 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 7,500 203,856 3.82 1.14 8,550 232,396
2019-09-20 2019-09-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 70,000 196,356 55.40
2019-06-04 2019-05-31 4 CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 50,000 126,356 65.48
2019-03-18 2019-03-15 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 10,000 76,356 15.07 1.36 13,600 103,844
2019-02-07 2019-02-05 4 CLSD Clearside Biomedical, Inc.
Employee Stock Option (right to buy)
A - Award 100,000 100,000
2018-03-26 2018-03-23 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 500 66,356 0.76 11.79 5,895 782,337
2017-12-12 2017-12-08 4 CLSD Clearside Biomedical, Inc.
Employee Stock Option (right to buy)
A - Award 96,000 96,000
2017-08-14 2017-08-14 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 1,000 65,309 1.55 7.06 7,065 461,408
2017-07-05 2017-06-30 4 CLSD Clearside Biomedical, Inc.
Common Stock
A - Award 1,550 64,309 2.47 7.74 11,997 497,752
2016-12-19 2016-12-15 4 CLSD Clearside Biomedical, Inc.
Employee Stock Option (right to buy)
A - Award 96,000 96,000
2016-07-25 2016-07-21 4 CLSD Clearside Biomedical, Inc.
Employee Stock Option (right to buy)
A - Award 30,000 30,000
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -470 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series B Preferred Stock
C - Conversion -9,375 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -2 62,759 0.00 7.00 -14 439,313
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
X - Other 470 62,761 0.75 0.02 10 1,381
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
C - Conversion 4,261 62,291 7.34
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
116,060
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
116,060
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)